ThermoGenesis Holdings (NASDAQ:THMO) reported quarterly losses of $(0.20) per share. This is a 47.37 percent increase over losses of $(0.38) per share from the same period last year.
Novo Nordisk Ups Outlook Amid Surging Demand For Weight Loss Drug Wegovy, Ozempic
Following a surge in demand for its weight-loss drug Wegovy and diabetes medication Ozempic, Novo Nordisk has revised its full-year outlook.
